30 closest matches · ranked by relevance
Locally Advanced Epithelioid Hemangioendothelioma · Metastatic Epithelioid Hemangioendothelioma · Unresectable Epithelioid Hemangioendothelioma
Primary: Objective Response Rate — 9.5 Percentage
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Fallopian Tube Cancer · Female Reproductive Cancer · Ovarian Carcinosarcoma
Primary: Objective Response Rate, Evaluated According to the RECIST Criteria — 0 participants
Carcinoma, Adrenal Cortical
Primary: Overall Survival — 108; 124 participants
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Progression Free Survival — 64 percentage of participants
Malignant PEComa
Primary: Objective Overall Response Rate (ORR) — 2; 10; 16; 3 Participants
Liposarcoma
Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants
Esophageal Cancer
Primary: Evaluation of Safety and Toxicity — 1; 1; 1; 1 participants
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Esophageal Cancer · Gastric Cancer
Primary: Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate — 54 Participants
Esophageal Cancer
Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
Hepatocellular Carcinoma
Primary: Freedom From Serious Adverse Event (SAE) at 30days — 22 participants
Carcinoma, Hepatocellular
Primary: Two Year Overall Survival — 65; 68 percentage of participants
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Adenocarcinoma of the Pancreas · Pancreatic Cancer · Recurrent Pancreatic Cancer
Primary: Objective Response (Complete and Partial) Evaluated Using RECIST Criteria — 0 participants
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Sarcoma, Alveolar Soft Part
Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants
Liver Cancer
Primary: Number of Participants With Toxicity Related to Electrochemotherapy — 20; 0; 0; 4 Participants
Ewing's Sarcoma · Primitive Neuroectodermal Tumor (PNET) · Askin's Tumor of the Chest Wall
Primary: Overall Response Rate (ORR) — 0 Participants
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: PFS Rate — 54.6 percentage of patients
Pleomorphic Rhabdomyosarcoma · Stage IIB Adult Soft Tissue Sarcoma AJCC v7 · Stage III Adult Soft Tissue Sarcoma AJCC v7
Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Locally Advanced Pancreatic Cancer · Pancreatic Cancer
Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Basal Cell Carcinoma
Primary: Progression Free Survival (PFS) of All Participants — 6; 36 weeks
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants